An in vitro experimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodies.
Kristina E AtanasoffLuca BrambillaDaniel C AdelsbergShreyas KowdleChristian S StevensChuan-Tien HungYanwen FuReyna LimLinh TranRobert AllenJ Andrew DutyGoran BajicBenhur LeeDomenico TortorellaPublished in: bioRxiv : the preprint server for biology (2023)
The COVID-19 pandemic remains a significant public health concern for the global population; development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as SARS-CoV-2 variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread with the caveat that they interact with the circulating variants. The epitope and binding specificity of a broadly neutralizing anti-SARS-CoV-2 Spike RBD antibody clone against many SARS-CoV-2 VOC was characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.